GBS, Inc. (GBS)

NASDAQ: GBS · IEX Real-Time Price · USD
0.710
+0.007 (0.95%)
At close: Aug 18, 2022 4:00 PM
0.710
0.000 (-0.014%)
After-hours: Aug 19, 2022 4:58 PM EDT
0.95%
Market Cap 10.57M
Revenue (ttm) 2.03M
Net Income (ttm) -7.08M
Shares Out 14.89M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,354
Open 0.730
Previous Close 0.703
Day's Range 0.690 - 0.730
52-Week Range 0.381 - 4.870
Beta n/a
Analysts n/a
Price Target 4.59 (+546.4%)
Earnings Date May 10, 2022

About GBS

GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The... [Read more...]

Industry Medical Devices
IPO Date Dec 23, 2020
Employees 7
Stock Exchange NASDAQ
Ticker Symbol GBS
Full Company Profile

Financial Performance

In 2021, GBS, Inc.'s revenue was $1.98 million, an increase of 949.30% compared to the previous year's $188,744. Losses were -$7.04 million, 122.4% more than in 2020.

Financial Statements

News

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022

NEW YORK, June 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology...

- Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which to leverage the existing GBS pipeline - Intelligent Fingerpri...

GBS Inc. to Present at the H.C. Wainwright Global Investment Conference

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at po...

GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at po...

GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval -

GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Me...

The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose

GBS Inc. to Participate in the Upcoming March Investor Conferences

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point...

GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government -

GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences

NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-...

GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

GBS Stock: The Covid Antibody Test News Shooting GBS Shares Higher Today

Shares of GBS stock are trading higher after a clinical study at Harvard University yielded positive results for the company's antibody test. The post GBS Stock: The Covid Antibody Test News Shooting GB...

GBS Shares Are Rallying On Plans For COVID-19 Antibody Trials After Validation Study

GBS Inc (NASDAQ:GBS) will prepare for clinical trials of its rapid SARS-CoV-2 (COVID-19) Antibody test following the recent successful completion of a clinical validation study. As previously referenced...

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –

GBS Inc. to Present First Quarter 2022 Financial Results and Recent Corporate Update on November 11

Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET

GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees,...

GBS Inc. Announces its Pre-Submission package is with the FDA

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at p...

GBS Inc. to Present at Upcoming September Virtual Investor Conferences

H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th

Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021. For some people with diabetes, testing with a pinprick is no more than a minor inconvenience.

GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-...